Literature DB >> 7836774

Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-1.

S Martin1, P Rieckmann, I Melchers, R Wagner, J Bertrams, A E Voskuyl, B O Roep, J Zielasek, E Heidenthal, I Weichselbraun.   

Abstract

The intercellular adhesion molecule-3 (ICAM-3) has been identified as the third LFA-1 ligand in addition to ICAM-1 and ICAM-2. In this report we have identified circulating forms of ICAM-3 (cICAM-3) in human serum. Using a sandwich ELISA with two monoclonal anti-ICAM-3 Abs, we detected cICAM-3 in concentrations between 40 and 360 ng/ml in all of 112 healthy controls. An analysis of patient sera from 10 different immune-mediated diseases revealed a distinct pattern of expression. Significantly elevated cICAM-3 levels were found in rheumatoid arthritis, systemic lupus erythematosus, Guillain-Barré syndrome, and multiple sclerosis, but not in type I diabetes, Grave's disease, chronic autoimmune thyroiditis, ulcerative colitis, or Crohn's disease. cICAM-3 levels were significantly higher in systemic lupus erythematosus patients with active compared with nonactive disease. Despite their binding to the same integrin receptor, serum levels of cICAM-3 did not correlate with cICAM-1 concentrations in either normal persons or in patients. The majority of patients had either elevated cICAM-3 or cICAM-1 levels but not both. In conclusion, a circulating form of ICAM-3 is present in human sera. cICAM-3 expression is elevated in certain immune-mediated diseases but occurs independently of cICAM-1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7836774

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Paul A Monach; Gunnar Tomasson; Ulrich Specks; John H Stone; David Cuthbertson; Jeffrey Krischer; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Ikle; Cees G M Kallenberg; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Yi-Zhong Gu; Ronald D Snyder; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2011-12

Review 2.  The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions.

Authors:  J S Hayflick; P Kilgannon; W M Gallatin
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 3.  The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure.

Authors:  Bart O Roep
Journal:  Diabetologia       Date:  2003-03-22       Impact factor: 10.122

4.  Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.

Authors:  Tao Liu; Wei-Jun Qian; Marina A Gritsenko; David G Camp; Matthew E Monroe; Ronald J Moore; Richard D Smith
Journal:  J Proteome Res       Date:  2005 Nov-Dec       Impact factor: 4.466

5.  Lymphocyte phenotypes in wild-caught rats suggest potential mechanisms underlying increased immune sensitivity in post-industrial environments.

Authors:  Ashley M Trama; Zoie E Holzknecht; Anitra D Thomas; Kuei-Ying Su; Sean M Lee; Emily E Foltz; Sarah E Perkins; Shu S Lin; William Parker
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

6.  Guillain-Barré Syndrome developing in a patient with Graves' Disease.

Authors:  Anirban Majumder; Sagar Basu
Journal:  J ASEAN Fed Endocr Soc       Date:  2019-05-23

Review 7.  The clearance of dying cells: table for two.

Authors:  D R Green; T H Oguin; J Martinez
Journal:  Cell Death Differ       Date:  2016-03-18       Impact factor: 15.828

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.